Seeking Alpha
15 Jul 2026, 17:45 UTC · 1h ago
Celcuity: 'Buy' REVTORPYK FDA Approval First And sNDA Label Expansion Q3 2026
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
15 Jul 2026, 17:45 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Celcuity received FDA approval for REVTORPYK as the first pan-PI3K, mTORC1/2 inhibitor for 2nd-line PIK3CA wild-type HR+/HER2- advanced breast cancer. — FDA approval of a first-in-class drug creates a new revenue stream and establishes a market lead for a specific patient cohort.
+0.80Phase 3 mutant cohort data underperformed relative to prior results, contributing to a rating downgrade from 'Strong Buy' to 'Buy'. — Weakening efficacy data in a key cohort reduces the potential total addressable market and long-term growth expectations.
-0.40The company faces rising competitive threats from Relay Therapeutics and a delayed commercial launch for REVTORPYK. — Competition and launch delays erode the 'first-mover' advantage and may compress future peak sales.
-0.30Continue reading
6 related stories
Top 3 movers · tap to explore
Celcuity plans a pivotal sNDA submission for label expansion in Q3 2026. — Label expansion provides a future catalyst for growth, though it is a long-term event.
+0.20The company has robust cash reserves sufficient to fund operations through 2027. — Strong liquidity reduces the immediate risk of dilutive financing, providing a stable floor for the valuation.
+0.10Which stocks this story touches
The company received FDA approval for REVTORPYK, though the analyst downgraded the stock from Strong Buy to Buy due to underperforming cohort data and competitive threats.
Mentioned as a rising competitive threat to Celcuity, implying a stronger market position or superior data.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
3h ago
